360 related articles for article (PubMed ID: 36926679)
21. Microarray profiling of hypothalamic gene expression changes in Huntington's disease mouse models.
Dickson E; Dwijesha AS; Andersson N; Lundh S; Björkqvist M; Petersén Å; Soylu-Kucharz R
Front Neurosci; 2022; 16():1027269. PubMed ID: 36408416
[TBL] [Abstract][Full Text] [Related]
22. Mutant Huntingtin Is Secreted via a Late Endosomal/Lysosomal Unconventional Secretory Pathway.
Trajkovic K; Jeong H; Krainc D
J Neurosci; 2017 Sep; 37(37):9000-9012. PubMed ID: 28821645
[TBL] [Abstract][Full Text] [Related]
23. Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes.
Juenemann K; Schipper-Krom S; Wiemhoefer A; Kloss A; Sanz Sanz A; Reits EAJ
J Biol Chem; 2013 Sep; 288(38):27068-27084. PubMed ID: 23908352
[TBL] [Abstract][Full Text] [Related]
24. Hunting for the cause: Evidence for prion-like mechanisms in Huntington's disease.
Donnelly KM; Coleman CM; Fuller ML; Reed VL; Smerina D; Tomlinson DS; Pearce MMP
Front Neurosci; 2022; 16():946822. PubMed ID: 36090278
[TBL] [Abstract][Full Text] [Related]
25. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
[TBL] [Abstract][Full Text] [Related]
26. Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.
Hakim-Eshed V; Boulos A; Cohen-Rosenzweig C; Yu-Taeger L; Ziv T; Kwon YT; Riess O; Phuc Nguyen HH; Ziv NE; Ciechanover A
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18661-18669. PubMed ID: 32675242
[TBL] [Abstract][Full Text] [Related]
27. Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review.
Zhao T; Hong Y; Li XJ; Li SH
Front Mol Neurosci; 2016; 9():27. PubMed ID: 27147961
[TBL] [Abstract][Full Text] [Related]
28. Proteostasis of Huntingtin in Health and Disease.
Koyuncu S; Fatima A; Gutierrez-Garcia R; Vilchez D
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753941
[TBL] [Abstract][Full Text] [Related]
29. Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons.
Tian J; Yan YP; Zhou R; Lou HF; Rong Y; Zhang BR
Neurosci Bull; 2014 Feb; 30(1):74-80. PubMed ID: 24362588
[TBL] [Abstract][Full Text] [Related]
30. Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease.
Naphade S; Embusch A; Madushani KL; Ring KL; Ellerby LM
Front Neurosci; 2017; 11():736. PubMed ID: 29459817
[TBL] [Abstract][Full Text] [Related]
31. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
Lu B; Palacino J
FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
[TBL] [Abstract][Full Text] [Related]
32. Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes.
Zhao T; Hong Y; Li S; Li XJ
J Neurosci; 2016 Aug; 36(32):8317-28. PubMed ID: 27511006
[TBL] [Abstract][Full Text] [Related]
33. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
34. Targeting the proteostasis network in Huntington's disease.
Soares TR; Reis SD; Pinho BR; Duchen MR; Oliveira JMA
Ageing Res Rev; 2019 Jan; 49():92-103. PubMed ID: 30502498
[TBL] [Abstract][Full Text] [Related]
35. Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23.
Yablonska S; Ganesan V; Ferrando LM; Kim J; Pyzel A; Baranova OV; Khattar NK; Larkin TM; Baranov SV; Chen N; Strohlein CE; Stevens DA; Wang X; Chang YF; Schurdak ME; Carlisle DL; Minden JS; Friedlander RM
Proc Natl Acad Sci U S A; 2019 Aug; 116(33):16593-16602. PubMed ID: 31346086
[TBL] [Abstract][Full Text] [Related]
36. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
37. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
38. Drugging unconventional targets: insights from Huntington's disease.
Yu S; Liang Y; Palacino J; Difiglia M; Lu B
Trends Pharmacol Sci; 2014 Feb; 35(2):53-62. PubMed ID: 24388390
[TBL] [Abstract][Full Text] [Related]
39. Time-resolved FRET screening identifies small molecular modifiers of mutant Huntingtin conformational inflexibility in patient-derived cells.
Wilbertz JH; Frappier J; Muller S; Gratzer S; Englaro W; Stanek LM; Calamini B
SLAS Discov; 2022 Jun; 27(4):219-228. PubMed ID: 35058188
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitin-activating enzyme activity contributes to differential accumulation of mutant huntingtin in brain and peripheral tissues.
Wade BE; Wang CE; Yan S; Bhat K; Huang B; Li S; Li XJ
J Neurosci; 2014 Jun; 34(25):8411-22. PubMed ID: 24948797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
